US FDA Takes Lilly’s Mounjaro, Zepbound Off Shortage List But Gives Compounding Grace Period

 
• By Sue Sutter
  
GLP-1 injection
Patients must transition away from compounded versions of Lilly's tirzepatide products in the next few months. (Shutterstock)

More from Litigation

More from Manufacturing